MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
1.820
+0.030
+1.68%
After Hours: 1.820 0 -0.01% 17:12 11/21 EST
OPEN
1.810
PREV CLOSE
1.790
HIGH
1.830
LOW
1.750
VOLUME
1.44M
TURNOVER
--
52 WEEK HIGH
2.480
52 WEEK LOW
0.8000
MARKET CAP
397.09M
P/E (TTM)
-8.2428
1D
5D
1M
3M
1Y
5Y
1D
Q3 2024 Earnings: Hold Akebia Therapeutics
Seeking Alpha · 1d ago
Weekly Report: what happened at AKBA last week (1111-1115)?
Weekly Report · 4d ago
Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In Hemodialysis Patients Who Were Converted From A Long-Acting Erythropoiesis-stimulating Agent To 3-Times Weekly Oral Vadadustat Dosing For The Maintenance Treatment Of Anemia
Benzinga · 11/14 13:26
Weekly Report: what happened at AKBA last week (1104-1108)?
Weekly Report · 11/11 10:41
Akebia Therapeutics Prepares for Vafseo Launch
TipRanks · 11/08 05:31
Akebia Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 11/07 14:15
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 11/07 13:15
*Akebia Therapeutics 3Q Loss/Shr 10c >AKBA
Dow Jones · 11/07 12:00
More
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.